A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
Ye ZhouXinhua ZhangXiaojun WuYongjian ZhouBo ZhangXiufeng LiuXin WuYan LiLin ShenJian LiPublished in: Cancer medicine (2020)
Dasatinib has modest antitumor activity with tolerable toxicities in patients with metastatic GISTs who have failed imatinib and sunitinib therapy.